Prognostic and predictive biomarkers for anti|EGFR monoclonal ...

Prognostic and predictive biomarkers for anti-EGFR monoclonal ...

In RAS wt mCRC patients receiving EGFR-targeted therapy, BRAF mutation is a powerful prognostic and therapy-predictive biomarker, ...

Prognostic and predictive biomarkers for anti-EGFR monoclonal ...

RAS mutations affect prognosis in patients with metastatic colorectal cancer (mCRC) and have been identified as strong negative predictive ...

Predictive and prognostic biomarkers with therapeutic targets in ...

The data showed that increased EGFR GCNwas generally associated with a better objective response, especially among patients with wild-type KRAS. In another meta ...

Predictive biomarkers for response to EGFR-directed monoclonal ...

Treatment with anti-EGFR monoclonal antibodies (mAbs) is associated with modest improvement in overall survival in patients with squamous cell lung cancer ( ...

Prognostic and predictive biomarkers for epidermal growth factor ...

The advent of the epidermal growth factor receptor (EGFR)-targeted monoclonal antibodies (mAbs), cetuximab and panitumumab has expanded the range of ...

Peer Review reports - BMC Cancer - BioMed Central

markers for anti-epidermal growth factor receptor monoclonal antibody (anti-EGFR ... From: Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody ...

(PDF) Prognostic and predictive biomarkers for anti-EGFR ...

Conclusions In RAS wt mCRC patients receiving EGFR-targeted therapy, BRAF mutation is a powerful prognostic and therapy-predictive biomarker, ...

is KRAS and BRAF wild type status required for anti-EGFR therapy?

Many potential biomarkers predictive of response to anti-EGFR monoclonal antibodies (cetuximab and panitumumab) have been retrospectively evaluated, including ...

Protein biomarkers predictive for response to anti-EGFR treatment in ...

Despite the advances in early diagnosis and treatment achieved in the past 20 years, prognosis of metastatic CRC (mCRC) remains relatively poor, ...

Predictive Biomarkers for Monoclonal Antibody Therapies Targeting ...

In this chapter we review clinical and molecular predictive markers of primary therapy response for metastatic colorectal cancer, focusing on anti-EGFR ...

Prognostic and predictive biomarkers in metastatic colorectal cancer ...

METHODS: The present study summarizes the potential value of prognostic and predictive biomarkers in selecting mCRC patients treated with anti-EGFR therapy.

Meta-analysis of BRAF mutation as a predictive biomarker of benefit ...

Based on the pharmacogenomic substudies of 8 RCTs, the hazard ratio for PFS benefit with anti-EGFR mAb therapy was 0.86 (95% CI; 0.61–1.21) for ...

Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor ...

The use of KRAS mutations as a selection biomarker for anti-EGFR monoclonal antibody (eg, panitumumab or cetuximab) treatment is the first major step toward ...

EGFR: A Prognostic and/or a Predictive Marker?

In the past, several “predictive” markers for clinical outcome after EGFR inhibitors have been reported. Activating mutations in the EGFR tyrosine kinase domain ...

is KRAS and BRAF wild type status required for anti-EGFR therapy?

Many potential biomarkers predictive of response to anti-EGFR monoclonal antibodies (cetuximab and panitumumab) have been retrospectively evaluated, including ...

Predictive Biomarkers to Anti-EGFR Inhibitors Treatment ... - IBB-CNR

amplification may be involved in primary resistance to anti-EGFR monoclonal antibodies ... colorectal cancer: assessment as prognostic and predictive biomarkers ...

Negative Predictive Biomarkers in Colorectal Cancer: PRESSING ...

This forms the biologic basis of identifying negative predictive biomarkers for anti-EGFR therapy. Mutations in KRAS exon 2 were the first ...

Prognostic and predictive biomarkers for anti-EGFR monoclonal ...

Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta- ...

Predictive Biomarkers - Translational Research | OncologyPRO

In colorectal cancer, KRAS is a frequently mutated oncogene and is a predictive biomarker for resistance to anti-EGFR monoclonal antibody therapy.

Predictive Biomarkers for Monoclonal Antibody Therapies Targeting ...

Clinical and molecular predictive markers of primary therapy response for metastatic colorectal cancer, focusing on anti-EGFR antibody therapies, ...